Introduction
============

Non-communicable diseases (NCD) have been the most common cause of human mortality, especially in developed countries, in recent years. Among the non-communicable diseases, cancer is an important factor for reducing life expectancy in all countries, especially in developed and developing countries ([@B1]). Colon cancer is the fourth most common cancer and the fifth leading cause of cancer deaths around the world ([@B2]). The incidence and mortality of colorectal cancer in Asia is increasing rapidly ([@B3]). According to the World Cancer Statistics, in 2018, colorectal cancer is the third most common cancer in Iran, accounting for 9% of all cancers. In the same year, colon cancer in Iran is ranked fourth in terms of incidence and fifth in terms of mortality ([@B4]). In low-risk countries such as Iran, the incidence of colorectal cancer has increased over the past three decades. The incidence of colorectal cancer varies depending on the geographic region. There is also a significant difference among different races and ethnic groups in terms of its mortality and incidence ([@B5]). The highest incidence of colorectal cancer was found in the central, northern and western provinces of the country and the lowest incidence was seen in southwestern provinces ([@B7], [@B6]). The increasing average age of the population and lifestyle changes are among of the causes of increased colorectal cancer in Iran ([@B8]). It is necessary to identify high risk groups and to take effective steps to screen the affected patients and improve the healthcare services provided and prevent this disease, as population, ethnicity and lifestyle vary in different regions of the country and given the high incidence of colorectal cancer in northern Iran. Therefore, the main aim of the present study was to evaluate the demographic, pathological, clinical characteristics and survival rate of colon cancer patients referred to Imam Khomeini Hospital in Sari during the years 2012-2017. These patients had follow up checks until April 2019.

Methods
=======

In this descriptive-analytical study, colon cancer patients hospitalized at Imam Khomeini Hospital in Sari during the years 2012-2017 were studied and their colon cancer was diagnosed definitively and follow up checks were carried out until April 2019 over the phone. A checklist was used to collect patient data and the standard of the checklist was confirmed by a medical research consultant. The checklist was completed by examining the patient medical records and via phone calls. The patients who had metastatic colon cancer or benign colon tumors were excluded from the study.

The demographic variables of the research included age at time of diagnosis, sex, place of residence, and history of heart disease, history of diabetes, family history of cancer, history of alcohol use, and history of tobacco use. The clinical, pathologic and therapeutic variables included patients' clinical symptoms at time of diagnosis, tumor primary site, type of tumor morphology, degree of tumor differentiation, lymph node involvement, and tumor stage, metastasis to other organs, local recurrence, treatment, and resection This information was extracted from medical records of the patients and by asking patients about their health status over the phone. The information was recorded in check lists. Patients had follow-up checks via phone calls and their survival rate was determined as failure time until the end of April 2019. Survival rate was defined as the time between cancer diagnosis until death or last follow-up.

For statistical analysis of the quantitative variables such as age, mean and standard deviation were calculated, and for statistical analysis of the classification variables, such as sex, ratio and percentage were calculated. Chi-square test was used to assess differences in qualitative variables and t-test and ANOVA were used to compare the means in two or more groups. The probability of survival was estimated from diagnosis time until death. Survival analysis in these patients was performed using Kaplan-Meier method and log-rank test. Data were analyzed through R software and the significance level was considered at 0.05.

Results
=======

###### 

Demographic characteristics of the patients with colon cancer in northern Iran (Mazandaran province) during 2012-2019

  Variable                          Sub-groups   Number of patients   Percentage of patients
  --------------------------------- ------------ -------------------- ------------------------
  Age at diagnosis time             17-39        29                   13
  40-49                             25           12                   
  50-59                             49           22                   
  60-69                             55           25                   
  70-79                             61           28                   
  Mean ± SD                         219          59.3±15.39           
  Gender                            Male         124                  57
  Female                            95           43                   
  Male: female ratio                1.3:1        \-                   
  Place of residence                urban        141                  64
  rural                             78           36                   
  History of heart disease          yes          64                   29
  no                                155          71                   
  History of diabetes disease       yes          49                   22
  no                                170          78                   
  Family history of cancer          yes          67                   31
  no                                152          69                   
  History of alcohol use            never        203                  93
  Previous or current consumption   16           7                    
  History of tobacco use            never        160                  73
  Previous or current consumption   59           27                   
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Out of all patients studied, 25% were younger than 50 years of age, 124 (56%) were male and the sex ratio was 1.3:1. Other data are shown in [Table 1](#T1){ref-type="table"}. The mean age was 59.89 ± 15.89 years in males and 58.54 ± 14.77 years in females, in other words, no significant difference was seen between males and females (p = 0.51). There was no significant difference between the mean ages in rural areas (59.97 ± 14.43) and urban areas (58.93 ± 15.94) (p = 0.62). The mean age of subjects with a family history of cancer (53.8 ± 16.9) was lower than that in patients without a family history of cancer (61.46 ± 14.11) and this difference was statistically significant (p= 0.001). However, family history of cancer had no significant relationship with sex (p = 0.42). The details of the demographic characteristics are presented in [Table 1](#T1){ref-type="table"}.

In terms of the initial symptoms of patients, based on the site of tumor involvement, rectorrhagia was observed more in patients with sigmoid tumor site and this relationship was statistically significant (p \<0.001). Abdominal pain was more seen in the patients with transverse and ascending tumor sites and this relationship was statistically significant (p = 0.01). The incidence of anemia was higher in the patients with ascending colon and caecum tumor site and it was statistically significant (p \<0.001). Other symptoms had no significant relationship with tumor site.

According to pathological indicators, cancer morphology in 188 (86%) patients with a mean age of 60.84 ± 14.67 years was adenocarcinoma and mucinous adenocarcinoma was seen in 21 (10%) patients with a mean age of 48.1 ±16.65 years and they had a lower mean age compared to adenocarcinoma and it was statistically significant (p = 0.002). Morphology type had no significant relationship with sex, tumor site and stage of cancer.

Degree of tumor differentiation was moderate in 125 cases (57%), well in 77 cases (35%) and poor in 17 cases (8%). The rate of well differentiation was seen more in the patients in stage A and poor differentiation was more seen in the patients at stage D and this relationship was statistically significant (p = 0.001).

###### 

The clinical and pathologic characteristics of the patients with colon cancer in northern Iran (Mazandaran province) during 2012-2019

  Variable                                             Subgroups             n     \%
  ---------------------------------------------------- --------------------- ----- ----
  The patient\'s clinical symptoms at diagnosis time   Rectorrhagia          79    36
  Abdominal pain                                       63                    29    
  Change in bowel habits                               37                    17    
  Anemia                                               20                    9     
  Weakness and lethargy                                7                     3     
  Weight loss                                          7                     3     
  Other cases                                          6                     3     
  The primary site of the tumor                        Caecum                28    13
  Ascending colon                                      34                    15    
  Transverse colon                                     17                    8     
  Descending colon                                     27                    12    
  Sigmoid                                              85                    39    
  Involvement of more than one site                    28                    13    
  Type of tumor morphology                             Adenocarcinoma        188   86
  Mucinous adenocarcinoma                              21                    10    
  Signet ring carcinoma                                5                     2     
  Intra mucosal adenocarcinoma                         3                     1     
  Mucin secreting adenocarcinoma                       1                     0.5   
  Ulcerative adenocarcinoma                            1                     0.5   
  Degree of tumor differentiation                      well differentiated   77    35
  moderately differentiated                            125                   57    
  poorly differentiated                                17                    8     
  Lymph node involvement                               N0                    127   58
  N1                                                   56                    26    
  N2                                                   36                    16    
  Tumor stage                                          A                     31    14
  B                                                    78                    36    
  C                                                    69                    31    
  D                                                    41                    19    
  Metastasis to other organs                           no                    146   66
  liver                                                37                    17    
  lung                                                 7                     3     
  Liver and lung                                       8                     4     
  Bladder                                              5                     2     
  Brain                                                2                     1     
  Other                                                14                    7     
  Local recurrence                                     yes                   72    33
  no                                                   147                   67    
  treatment                                            Surgery               15    7
  Surgery + Chemotherapy                               146                   67    
  Surgery + Radiotherapy                               20                    9     
  Surgery + Chemotherapy + Radiotherapy                38                    17    
  Resection                                            partial colectomy     91    42
  total colectomy                                      45                    20    
  right hemicolectomy                                  38                    17    
  partial resection                                    31                    14    
  left hemicolectomy                                   12                    5     
  subtotal colectomy                                   2                     1     

###### 

The overall survival rate based on cancer stage of the patients with colon cancer in Northern Iran (Mazandaran Province) during 2012-2019

  survival rate   1-year   2-year   3-year   4-year   5-year   6-year   7-year
  --------------- -------- -------- -------- -------- -------- -------- --------
  general         0.88     0.76     0.70     0.59     0.49     0.39     0.37
  Stage A         0.99     0.87     0.87     0.83     0.83     0.59     0.59
  Stage B         0.91     0.83     0.78     0.73     0.67     0.56     0.56
  Stage C         0.87     0.77     0.67     0.53     0.44     0.39     0.31
  Stage D         0.78     0.54     0.46     0.27     0.06     \-       \-
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The degree of tumor differentiation had no statistically significant relationship with sex, age and morphology.

The number of involved lymph nodes was N0 in 127 cases (58%), N1 in 56 cases (26%) and N2 in 36 cases (16%). There was no significant relationship between the number of lymph nodes involved and sex, age at diagnosis, morphology type and tumor differentiation.

Most patients (n=78, 36%) were diagnosed at stage B of colon cancer, 69 (31%) patients in stage C, 41 (19%) patients in stage D, and 31 (14%) patients in stage A and cancer stage did not show a significant relationship with sex and age.

Seventy (34%) patients had tumor metastasis to other organs, of which 36 (51%) had liver metastasis and 19% had metastasis at diagnosis time (15% had metastasis after surgery). At stage D, metastasis was more in liver and lung and it was statistically significant (P \<0.001). Seventy-one patients (33%) had local recurrence.

Sixty-eight percent of patients underwent surgery and chemotherapy, 17% of patients underwent surgery and radiotherapy and chemotherapy, 9% of patients underwent surgery and radiotherapy and 6% of patients underwent surgery alone. The clinical and pathologic characteristics of patients are presented in [Table 2](#T2){ref-type="table"}.

All subjects had follow-ups. The mean follow-up was 42.10 months and the longest follow-up was 84 months. During the study period, 108 patients died. The mean age of these patients was 60.56 ± 15.48 years, of which 61 (56.48%) were male. Median and mean life expectancy of the patients were 60 and 53.71 ± 2.07 months, respectively. One, three, five, and seven-year survival rate was estimated to be 88, 70, 49, 37%, respectively, as shown in [figure 1](#F1){ref-type="fig"}.

As shown in [figure 2](#F2){ref-type="fig"}, 5-year survival rate was estimated at 83% for stage A, 67% for stage B, 44% for stage C, and 6% for stage D. The details of survival rates are presented in [Table 3](#T2){ref-type="table"}.

###### 

Comparison of survival of patients with colon cancer in northern Iran (Mazandaran Province) during the years 2012 to 2019 separately for demographic, clinical and pathologic characteristics

  Variable                                             Sub-groups            Number of patients   Number of died people   Mean survival time ± SE in month   Survival rate                 
  ---------------------------------------------------- --------------------- -------------------- ----------------------- ---------------------------------- --------------- ------ ------ ---------
  Total                                                \-                    219                  108                     2.07±53.71                         0.70            0.49   0.37   \-
  age during diagnosis                                 17-49                 54                   22                      4.02±59.1                          0.75            0.57   \-     0.3
  50-69                                                104                   53                   52.8±2.97               0.68                               0.52            0.32          
  70-90                                                61                    33                   4.04±50.6               0.66                               0.38            0.38          
  Gender                                               male                  124                  61                      2.86±53                            0.70            0.45   0.42   0.7
  female                                               95                    47                   2.97±54                 0.70                               0.56            0.31          
  Place of residence                                   urban                 141                  70                      2.55±53.5                          0.71            0.47   0.34   0.8
  rural                                                78                    38                   3.58±54                 0.68                               0.54            0.40          
  History of heart disease                             yes                   64                   30                      4.05±53.7                          0.69            0.55   0.36   0.8
  no                                                   155                   78                   2.40±53.7               0.70                               0.47            0.36          
  History of diabetes                                  yes                   49                   20                      4.62±57.2                          0.69            0.56   0.51   0.3
  no                                                   170                   88                   2.31±52.8               0.70                               0.48            0.33          
  Family history of cancer                             yes                   67                   31                      3.40±57.7                          0.79            0.54   0.38   0.3
  no                                                   152                   77                   2.57±52                 0.66                               0.47            0.36          
  History of alcohol use                               never                 203                  100                     2.08±53.3                          0.7             0.50   0.35   0.99
  Previous or current use                              16                    8                    8.28±51.5               0.69                               0.50            \-            
  History of tobacco use                               never                 160                  81                      2.40±51.9                          0.70            0.45   0.33   0.2
  Previous or current use                              59                    27                   3.95±56.09              0.70                               0.58            \-            
  The patient\'s clinical symptoms at diagnosis time   Rectorrhagia          79                   39                      3.30±52.4                          0.66            0.48   0.35   \<0.001
  Abdominal pain                                       63                    36                   3.69±47.4               0.63                               0.39            0.27          
  Change in bowel habits                               37                    19                   4.5±53                  0.78                               0.50            0.33          
  Anemia                                               20                    5                    6.17±64.8               0.84                               0.77            \-            
  Weakness and lethargy                                7                     1                    5.82±74.7               1                                  0.86            0.86          
  Weight loss                                          7                     2                    9.09±66.7               0.86                               0.86            0.57          
  Other cases                                          6                     6                    6.49±23.8               0.33                               \-              \-            
  The primary site of the tumor                        Caecum                28                   14                      5.22±54.7                          0.71            0.52   \-     0.1
  Ascending colon                                      34                    13                   4.97±59.5               0.75                               0.62            0.52          
  Transverse colon                                     17                    6                    7.25±60.3               0.71                               0.71            \-            
  Descending colon                                     27                    17                   5.65±43.1               0.60                               0.25            0.25          
  Sigmoid                                              85                    46                   3.21±49                 0.68                               0.43            \-            
  Involvement of more than one site                    28                    12                   5.45±58.3               0.79                               0.59            0.39          
  Type of tumor morphology                             Adenocarcinoma        188                  91                      1.64±47.4                          0.71            0.50   0.39   0.65
  Mucinous adenocarcinoma                              21                    13                   5.21±41                 0.57                               0.45            \-            
  Signet ring carcinoma                                5                     2                    12.26±44                0.6                                \-              \-            
  Other cases                                          5                     2                    6.22±54.8               0.75                               \-              \-            
  Degree of tumor differentiation                      well differentiated   77                   33                      3.29 ±59                           0.74            0.58   0.44   0.006
  moderately differentiated                            125                   62                   2.82±52.9               0.67                               0.49            0.37          
  poorly differentiated                                17                    13                   5.23±34.4               0.50                               0.25            \-            
  Lymph node involvement                               N0                    127                  54                      2.71±57.8                          0.74            0.57   0.44   0.02
  N1                                                   56                    30                   4.19±51.21              0.67                               0.45            0.35          
  N2                                                   36                    24                   4.53±43.51              0.56                               0.23            \-            
  Tumor stage                                          A                     31                   7                       4.8±69.3                           0.87            0.83   0.59   \<0.001
  B                                                    78                    27                   3.26±63.4               0.78                               0.67            0.56          
  C                                                    69                    37                   .3.69±51                0.67                               0.44            0.31          
  D                                                    41                    37                   3.07±31.1               0.46                               0.06            \-            
  Metastasis to other organs                           no                    146                  45                      1.39±49.5                          0.85            0.70   0.54   \<0.001
  liver                                                37                    31                   3.10±34.5               0.50                               0.16            0.04          
  lung                                                 7                     7                    5.96±22                 0.14                               \-              \-            
  Liver and lung                                       8                     8                    6.18±26.5               0.25                               \-              \-            
  Other organs                                         21                    17                   4.42±30.4               0.38                               0.08            \-            
  Local recurrence                                     yes                   72                   43                      3.23±52.6                          0.66            0.45   0.31   0.43
  no                                                   147                   65                   2.68±54.7               0.72                               0.52            0.41          
  treatment                                            Surgery               15                   8                       8.12±41.3                          0.67            0.20   \-     0.37
  Surgery Chemotherapy+                                146                   70                   2.39±53.08              0.72                               0.50            0.40          
  Surgery Radiotherapy +                               20                    8                    6.74±56.7               0.65                               0.59            \-            
  Surgery +Chemotherapy +Radiotherapy                  38                    22                   4.34±48.8               0.65                               0.47            0.12          
  Resection                                            partial colectomy     91                   49                      3.15±50.2                          0.64            0.43   0.34   0.13
  total colectomy                                      45                    20                   4.45±53.6               0.71                               0.58            0.22          
  right hemicolectomy                                  38                    14                   3.9±64.4                0.84                               0.67            0.55          
  partial resection                                    31                    16                   5.69±44.4               0.66                               0.40            \-            
  left hemicolectomy                                   12                    8                    8.14±45.1               0.67                               0.34            \-            
  subtotal colectomy                                   2                     1                    14.14±62                1                                  0.50            \-            

A noteworthy relationship was not observed between age at diagnosis time, sex, place of residence, history of heart disease, history of diabetes, family history of cancer, history of alcohol use, history of tobacco use, primary tumor site, type of tumor morphology, local recurrence, treatment, resection and survival rate. However, this rate was affected by the patient\'s clinical symptoms at diagnosis time, degree of tumor differentiation, lymph node involvement, tumor stage at diagnosis time, and metastasis to other organs ([Table 4](#T4){ref-type="table"}).

Discussion
==========

According to the results of the present study, adenocarcinoma tumor was observed in most patients and mucinous adenocarcinoma tumor was observed in 10% of patients who were nearly 49 years old at diagnosis time. In European countries, mucinous adenocarcinoma accounts for 10--20% of colorectal cancer cases and it is most commonly observed in patients under the age of 50 years and in the right colon ([@B9], [@B10]).

The rate of local recurrence in the patients was 33%. Local recurrence leads to death, if left untreated. Its incidence varies depending on the tumor stage ([@B11]). Distant metastasis was 15% (except for stage D metastasis) and it was seen more in the liver. In a study conducted by Keshvari et al., the rate of local recurrence and metastasis in colon cancer was reported at 16.44% and 10.96%, respectively ([@B12]). A good surgical technique can keep the local recurrence below 10% and keep the metastasis below 20% ([@B13]). Since our patients showed a higher percentage of local recurrence and the rate of recurrence depends on several factors, such as the stage of tumor, rate of cell differentiation, and surgical experience, investigating its causes requires a more comprehensive examination.

In the current study, as with other studies, the number of males was higher and the ratio of males to females was 1.3:1 ([@B14], [@B15], and [@B16]). The mean age of diagnosis was 59 years, 13% of patients were younger than 40 years of age and about 25% of patients were under 50 years of age. In one of the previous studies, the mean age of patients was 52.6 years and 33.4% of patients were younger than 45 ([@B15]). In a study conducted by Mirzaeipour et al., the mean age of patients was 58.02 years and 17% of patients were younger than 45 ([@B16]), indicating increasing age of disease diagnosis. If it is at a lower stage and higher age at diagnosis time, it will indicate improved lifestyle.

In the study conducted by Hajmanoochehri et al., the mean age of patients was 57.3 years and 29.2% of the patients were younger than 50 ([@B17]). In the study conducted by Fatemi et al., the mean age of patients was 53.5 years ([@B18]). In Iran, almost one fifth of all cases of colorectal cancer occur in people younger than 40 years of age ([@B8], [@B19]). The results of the studies in western countries show that 2.6% of colorectal cancer cases occur in people under 40 years of age and 10% in people younger than 50 years of age ([@B20]). The results of this study and previous studies in Iran show that the age distribution in Iran is lower than that of western countries.

Most patients lived in urban areas, since physical activity was significantly associated with a reduced risk of certain cancers in particular locations, especially colon cancer, and it reduces the risk of the disease by approximately 30-40% ([@B21]). People who live in rural areas are more physically active than those living in urban areas and as they have a more vegetable-rich diet, they have reduced risks of cancer.

A family history of cancer was found in 30% of people and most of them were younger than 53 years of age. In many studies, 24% to 45% of patients had a family history of cancer ([@B14], [@B15], [@B16], and [@B22]).

A positive family history is considered a risk factor for colon cancer ([@B23]) and it increases the risk of cancer at ages below 50 ([@B24]). In the study conducted by Salimzadeh et al., only 28% of first-degree relatives of patients with colon cancer were aware that they were at risk of cancer and 88% of relatives were not aware about the right age to start screening ([@B25]). It indicates poorer knowledge of people about screening. As lack of knowledge and proper training can help increase the incidence of colorectal cancer, the need to increase people's awareness about early diagnosis for people at risk, especially people with a positive family history, is critical in improving community health.

In terms of anatomic site, the greatest tumor lesion was in the sigmoid site (38%). In a study conducted by Golfam et al. In 2012, in Tehran, the most common site for colorectal cancer was rectum following sigmoid ([@B26]). In Asian countries such as Malaysia and Oman, sigmoid was the most common site involved in colon cancer ([@B27], [@B28]). Rectorrhagia and abdominal pain were the most common clinical symptoms that patients complained of when they referred to medical centers. Initial symptoms of the patients vary depending on the tumor involvement site, so that change in bowel habits is a common symptom in the left colon; whereas, right colon cancer usually shows symptoms such as anemia, iron deficiency, fatigue and weakness. Rectorrhagia often occurs in the rectum and sigmoid. Abdominal pain can occur in tumors grown in all locations ([@B29], [@B30]). This association between patients\' initial symptoms and the tumor involvement site is consistent with the results of our study.

About half of the patients referred to medical centers at an advanced stage of their disease (D, C), which can be due to increased risk factors, lack of knowledge of symptoms, ignoring gastrointestinal symptoms, outpatient treatment of gastrointestinal problems, and lack of timely diagnosis and treatment.

Three-year, five-year, and seven-year survival rates in the patients with colon cancer were estimated to be 0.70, 0.49, and 0.37%, respectively. Akhoond et al. in Tehran reported that 3-year and 5-year survival rates to be 68.5% and 56.8%, respectively ([@B31]). Asghari-Jafarabadi et al. in Tehran reported 3-year and 5-year survival rate to be 75.9% and 63.3%, respectively ([@B32]). However, in the study conducted by Gohari et al. in Tehran, 3-year and 5-year survival rates were reported to be 71% and 48%, respectively ([@B33]). In general, studies in Iran have reported a 5-year survival rate at 48 to 75.2% in the patients with colon cancer ([@B18], [@B33]). In Asian countries such as Malaysia in 2010 and China in 1992-1995, 5-year survival rate in colon cancer was reported at about 44% ([@B34], [@B35]). In a study conducted in Turkey during 2009--2013, 5-year survival rate was reported to be 56.7%. The high survival rate in the mentioned study may be due to the low number of patients (5 patients) at stage D ([@B36]). In a population-based study conducted in USA during 2007--2015, the three-year and five-year survival rates were reported to be 70% and 60.02%, respectively ([@B37]). One of the reasons for the low survival rate may be the later referral of the patients and the diagnosis of disease at an advanced stage, which leads to lower survival rates. In our study, half of the patients were diagnosed at advanced stages.

In this study, the five-year survival rate was at 83% for stage A, 67% for stage B, 44% for stage C, and 6% for stage D, which was significant in univariate analysis, so that survival rate decreases with the increase in the stage of disease. In other studies, a strong association has been also reported between tumor stage and survival rate ([@B37]-[@B39]). In the study conducted by Lee et al. in Taiwan (2007-2007), the five-year survival rate of colorectal cancer patients was 92.2% at stage A, 82.2% at stage B, 63.2% at stage C, and 21.7% at stage D ([@B40]).

It has been found that with increasing lymph node involvement, survival rate decreases. It was also found that the degree of tumor differentiation was effective in survival and the patients with poor differentiation had lower survival rate. Poorly differentiated tumors tend to metastasize, leading to reduced survival in patients; while, well or moderately differentiated tumors have a better prognosis ([@B41]). The effect of lymph nodes and the rate of tumor differentiation have been confirmed in various studies ([@B31], [@B32], [@B40]-[@B42]).

Other studies have also reported that metastasis to other organs had a significant effect on patient survival ([@B41], [@B42]). For example, in the study conducted by Akhoond et al. and Lee et al. ([@B31], [@B40]), metastasis to other organs has been reported as an effective factor. Initial symptoms of the patient at diagnosis time had a significant relationship with survival rate, but the results of this study show no significant relationship between survival rate and the demographic variables included in the study. These results were confirmed in some studies ([@B43], [@B44]); while, differences were reported in some other studies ([@B31], [@B32], [@B42]).

Finally, it can be concluded that a significant percentage of patients had a positive family history and about one-third of patients had local recurrence. Further investigations are needed in other studies. Healthy nutrition, exercise, and patient referral at suitable intervals are effective strategies in preventing the disease recurrence. Half of the patients were in stages C and D at diagnosis time. The mean survival time at advanced stages was approximately four years and the survival rate of patients in this province is low, therefore, providing effective training to enhance the knowledge of people with respect to colon cancer and initial symptoms of disease can play a major role in controlling and preventing this type of cancer. Colorectal cancer is a preventable cancer, so it is necessary to identify risk factors and pay attention to gastrointestinal symptoms in patients, do screening tests, especially in people with a positive family history and those who are over 45 years of age. These measures are effective in diagnosing the disease at an early stage, providing better treatment and consequently increasing the survival rate and reducing mortality rate of patients.
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